Abbott Laboratories (NYSE:ABT) Issues FY 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 5.450-5.60 for the period, compared to the consensus earnings per share estimate of 5.480. The company issued revenue guidance of -. Abbott Laboratories also updated its Q3 2026 guidance to 1.380-1.46 EPS.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $98.81 on Friday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The firm has a market cap of $172.11 billion, a P/E ratio of 27.68, a P/E/G ratio of 1.54 and a beta of 0.61. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average of $89.56 and a 200-day moving average of $102.18.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. Abbott Laboratories’s payout ratio is 70.59%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ABT shares. Leerink Partners cut their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. Wells Fargo & Company reduced their price target on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Piper Sandler reissued an “overweight” rating and set a $115.00 target price on shares of Abbott Laboratories in a report on Monday, June 22nd. Jefferies Financial Group reduced their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, TD Cowen cut their target price on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $117.61.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by company insiders.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported Q2 adjusted EPS of $1.31, topping estimates, while revenue rose 13% year over year and sales growth was broad-based across medical devices, diagnostics, and nutrition. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: The company raised 2026 adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58, which suggests management is seeing better profitability trends than Wall Street expected. Abbott raises 2026 profit forecast on heart device strength
• Positive Sentiment: Investor sentiment improved because demand for Abbott’s heart devices and diagnostics appears to be strengthening, especially after management pointed to a better second-half outlook and continued momentum in those segments. Why Abbott Stock Jumped Today
• Neutral Sentiment: Abbott continues to trade well above its recent 50-day average, but it remains below its 200-day average, so the longer-term trend is still mixed despite the earnings-driven rebound.
• Negative Sentiment: Some headlines note that the stock had been under pressure earlier this year, and while the latest results helped, concerns about the broader trend and valuation are not fully gone. Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?

Institutional Investors Weigh In On Abbott Laboratories

A number of large investors have recently added to or reduced their stakes in ABT. Brighton Jones LLC increased its position in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Pinnacle Financial Partners Inc. lifted its position in Abbott Laboratories by 21.0% during the third quarter. Pinnacle Financial Partners Inc. now owns 122,698 shares of the healthcare product maker’s stock worth $16,434,000 after purchasing an additional 21,301 shares during the period. Sivia Capital Partners LLC grew its stake in Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after buying an additional 162 shares in the last quarter. United Bank increased its holdings in Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the period. Finally, Quattro Advisors LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at approximately $113,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.